Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Florida Pulmonary Group P A

Neither a doctor nor a teaching hospital

Research payments

$385,616

157 payments

Through program year 2025, Central Florida Pulmonary Group P A is reported as receiving $385,616 in research payments, across 157 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $91,828 39
2024 Research $142,992 46
2023 Research $52,163 23
2022 Research $42,639 11
2021 Research $20,788 6
2020 Research $10,462 9
2019 Research $24,745 23

Breakdown

Who paid Research payments · program years 2019–2025
  1. United Therapeutics Corporation $385,616 157 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $177,887 53 payments
  2. An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $124,254 49 payments
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to Pah Standard of Care Or Pah-Specific Background Oral Therapy in Subjects With Who Group I Pulmonary Hypertension $28,688 13 payments
  4. Adapt - A Patient Registry of the Real-World Use of Orenitram $21,791 17 payments
  5. A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With Pah Via An Open-Label Extension $13,691 5 payments
  6. A Multicenter Randomized Double-Blinded Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease $5,249 4 payments
  7. An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease $5,249 4 payments
  8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension PH in Heart Failure With Preserved Ejection Fraction Hfpef $4,621 5 payments
  9. An Open-Label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension PH Associated With Heart Failure With Preserved Ejection Fraction Hfpef - A Long-Term Follow-Up to Study Tde-Hf-301 $3,730 5 payments
  10. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (Hfpef) $228 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record